The seed round was led by Khosla Ventures with participation from Entrepreneur First and angel investors.
"At GOSH, we’re committed to rigorously trialling the best new clinical technologies to generate valuable data and evaluate their impact. We’re very excited to have this opportunity to partner with TORTUS and to study how generative AI tools could help our clinicians by safely freeing them from administrative tasks and allowing them to spend more time directly interacting with patients."
The oversubscribed round will fund commercial expansion and the development of new artificial intelligence capabilities.
"The sector is in a well-documented state of crisis, and we have empirically proved how we can alleviate pressures of diminishing budgets, resources and even bankruptcy that local governments are facing. This success and evidence is what has delivered investor confidence and powered this oversubscription."
TELUS Ventures backed the seed round to help the mental health platform expand its presence in North America.
"No one should struggle alone, and we believe that peer support has the power to break the stigma around mental health. Technology allows us to create safe spaces for people to connect and share whenever they need to and wherever they are. TalkLife is pioneering a new kind of mental health support that’s accessible, relevant, and has the research backing to prove that it really works. With the support of TELUS Ventures and TELUS Health, we will be able to power our growth and reach millions more people through both our free app and our specialized platforms for students and employees."
Morgan Stanley led the seed round to support platform expansion and data science development.
"Despite 90% of the UK’s 33.8 million female population experiencing monthly hormonal symptoms, women’s health has for too long been fragmented and underserved. Unfabled has already empowered thousands of women to find effective treatments for common, yet hugely disruptive, hormonal and reproductive conditions like PMS, Polycystic Ovary Syndrome (PCOS), endometriosis and menopause."
Private equity firm Traditum has backed the healthcare software provider in its fourth funding round.
"The investment from Traditum is an endorsement of our mission to transform independent pharmacies through digitising the sector. Our goal is ultimately about providing better primary care for communities and enabling healthcare professionals to do so more effectively. With this backing we are positioned to expand our international reach as well as our capabilities to enhance the quality of care our customers can provide to patients."
